title: Endogenous endophthalmitis associated with intravenous drug abuse.
abstract: OBJECTIVE
  To describe demographics, characteristics, and management of eyes with endogenous endophthalmitis (EE) in intravenous drug abusers.
  
  
  METHODS
  Retrospective chart review of patients with EE who presented to University Hospital, New Jersey Medical School between January 2005 and October 2012.
  
  
  RESULTS
  Thirty-four patients presented with a clinical diagnosis of EE during this time period. Eighteen patients (53%) had a history of intravenous drug abuse with at least 15 of the 18 patients reporting intravenous heroin abuse. Average age was 43 years (24-61 years), 13 were men. Three patients had bilateral involvement. Mean time from the onset of symptoms to presentation was 10 days (range, 1-42 days). Presenting vision in the affected eye ranged from 20/100 to no light perception; the majority of patients had vision of counting fingers or worse. All patients were admitted to the hospital for intravenous antimicrobials and further workup. Final best-corrected visual acuity at the last follow-up ranged from 20/20 to no light perception, with most patients having final vision of 20/400 or worse.
  
  
  CONCLUSIONS
  We reviewed 21 eyes of 18 patients with EE and concurrent intravenous drug abuse over an 8-year period; our study shows extremely poor visual prognosis associated with EE in this setting.
authors.affiliation: Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.
authors.forename: Shriji N
authors.initials: SN
authors.lastname: Patel
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Rescigno
authors.forename: Marco A
authors.initials: MA
authors.lastname: Zarbin
authors.forename: Paul
authors.initials: P
authors.lastname: Langer
authors.forename: Neelakshi
authors.initials: N
authors.lastname: Bhagat
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000302:isolation & purification; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D015821:Eye Infections, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D005658:Fungi / Q000302:isolation & purification; D006556:Heroin Dependence / Q000150:complications*; D006801:Humans; D007262:Infusions, Intravenous; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications*; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents